Core Viewpoint - The implementation of the new National Medical Insurance Drug List and the Commercial Health Insurance Innovative Drug List in 2025 marks a significant step towards addressing the payment challenges for high-value innovative drugs, enhancing the role of commercial health insurance in multi-tiered medical security [1][2][3] Group 1: Policy Implementation - The new drug lists will be executed starting January 1, 2026, with the commercial health insurance list including 19 innovative drugs, notably five CAR-T cancer treatment drugs [1][2] - The introduction of the "dual directory" system aims to bridge the gap between basic medical insurance and commercial health insurance, facilitating access to high-value drugs for more patients [1][5] Group 2: Commercial Health Insurance Role - The commercial health insurance sector is expected to innovate and expand coverage in response to the new drug lists, potentially allowing more patients to access expensive treatments [1][3][6] - The "three exclusions" policy will enable hospitals to prescribe high-priced innovative drugs more freely, thus improving clinical accessibility and allowing for smoother commercial health insurance settlements [4][6] Group 3: Market Dynamics - As of 2024, commercial health insurance premiums reached 977.3 billion yuan, yet only contributed 7.7% to the innovative drug market, indicating untapped potential in this sector [8] - The dual directory system is seen as a crucial step in building a high-quality multi-tiered medical security system, aiming to resolve the issue of high-value drugs being available but not affordable [8][9] Group 4: Future Considerations - Experts emphasize the need for a collaborative platform to enhance negotiation power between insurance companies and pharmaceutical firms, as well as the importance of data management and actuarial pricing for sustainable product offerings [9] - There is a call for establishing dynamic connection mechanisms between the medical insurance and commercial insurance directories to ensure smooth transitions and effective patient support [9]

Core Points - The National Healthcare Security Administration (NHSA) has launched a new version of the basic medical insurance directory and the first commercial health insurance innovative drug directory on January 1 [1] - The updated directories were officially released in December 2025, providing users with a convenient way to check drug information through the NHSA WeChat public account [1] Group 1: New Features - Users can access the new drug directories by navigating to the "Microservices" section of the NHSA WeChat account and selecting the appropriate query options [1] - The search functionality allows users to input the generic name of a drug to determine its inclusion in the directory, classification, and reimbursement category [1] Group 2: Drug Classification - The NHSA classifies drugs in the medical insurance directory into two categories: Class A and Class B [2] - Class A drugs are essential for clinical treatment, widely used, and have proven efficacy, with full reimbursement available for insured individuals [2] - Class B drugs are also clinically effective but are priced slightly higher than Class A drugs, requiring individuals to pay a portion out-of-pocket before reimbursement [2]

Group 1 - The new version of the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Directory has been implemented, adding 114 new drugs to the reimbursement list, including 50 first-class innovative drugs, while removing 29 drugs that are either not clinically available or can be replaced by better alternatives [2] - The total number of drugs in the directory has increased to 3,253, with 1,857 Western medicines and 1,396 traditional Chinese medicines, significantly enhancing coverage for key areas such as cancer, chronic diseases, mental illnesses, rare diseases, and pediatric medications [2] Group 2 - Starting today, all medical institutions are required to fully collect and upload drug traceability codes, which serve as "electronic IDs" for drugs, ensuring traceability throughout the production, circulation, usage, and insurance settlement processes [3] - The National Medical Insurance Information Platform has collected 110.369 billion traceability codes, aiding in the resolution of multiple national counterfeit drug cases and addressing 39,100 illegal institutions, with 188 cases referred to judicial authorities [3][5] Group 3 - A new policy requires kindergartens to implement a directory management system for fees, establishing two separate lists for service fees and kindergarten-specific charges, with strict public disclosure requirements [6] Group 4 - The People's Bank of China will automatically adjust credit information based on repayment conditions, with specific criteria set for overdue debts occurring between January 1, 2020, and December 31, 2025, allowing for the removal of certain overdue information from personal credit reports if conditions are met [8] - The new VAT law and its implementation regulations have come into effect, with 14 out of 18 existing tax types now having legal frameworks, covering a significant portion of tax revenue [8]

Core Insights - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security announced the new National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025) and the Commercial Health Insurance Innovative Drug Catalog (2025), which will be implemented nationwide starting January 1, 2026 [1][2] Group 1: National Basic Medical Insurance Drug Catalog - The updated National Medical Insurance Drug Catalog includes 114 new drugs, of which 50 are first-class innovative drugs [1] - A total of 29 drugs that are either not clinically available or can be better replaced by other medications have been removed from the catalog [1] - The total number of drugs in the catalog has increased to 3,253, comprising 1,857 Western medicines and 1,396 traditional Chinese medicines, with significant improvements in coverage for key areas such as oncology, chronic diseases, mental illnesses, rare diseases, and pediatric medications [1] Group 2: Commercial Health Insurance Innovative Drug Catalog - The inaugural Commercial Health Insurance Innovative Drug Catalog includes 19 drugs, which complement the basic medical insurance effectively [2] - This initiative lays the groundwork for the complementary development of commercial insurance and basic medical insurance, contributing to the establishment of a multi-tiered medical security system [2]

Core Insights - The National Healthcare Security Administration (NHSA) held a conference on December 9, 2023, to discuss the 2025 Medical Insurance Drug List, attracting significant interest from various stakeholders, including over 23,000 online viewers [1][6]. Group 1: Drug List Adjustments - The basic medical insurance fund, exceeding 3 trillion yuan, is directly linked to the annual release of the National Medical Insurance Drug List [6]. - In 2025, 114 new drugs were added to the basic medical insurance list, with 111 being new drugs launched within the last five years, marking a record high in both proportion and quantity [7]. - The adjustment process for the drug list has become clearer, with specific phases for preparation, application, review, and negotiation [7]. Group 2: Misunderstandings in Drug Pricing - There are misconceptions regarding the negotiation process, particularly the belief that all drugs must reduce prices upon renewal; only 30 out of 178 drugs negotiated for renewal experienced an average price drop of 13.8% [8]. - The average price reduction for the 15 drugs that were renewed was only 8.4% [8]. Group 3: Commercial Health Insurance Innovations - The NHSA introduced the first Commercial Health Insurance Innovative Drug List, which involves a more complex review process, including a re-evaluation by a specialized expert group [9]. - Certain drugs, while deemed valuable by basic medical insurance experts, were not included in the commercial insurance list due to concerns over their insurability and management difficulties [10]. Group 4: Challenges in Implementation - The NHSA aims to leverage the "three exclusions" policy to facilitate drug inclusion in hospitals and encourage the design of insurance products targeting the innovative drug list [11]. - There are significant challenges in aligning commercial insurance products with the innovative drug list, including low efficiency in claims processing and insufficient coverage [12]. Group 5: Differentiated Innovation in Pharmaceuticals - The NHSA emphasizes the need for differentiated innovation in pharmaceuticals, urging companies to provide robust evidence, such as head-to-head clinical trial data, to support claims of being "best in class" [15][16]. - The selection of reference drugs for economic evaluation is crucial, requiring a comprehensive approach that considers multiple dimensions of comparison [16][17].

Group 1 - The 2025 Innovative Drug High-Quality Development Conference was held in Guangzhou on December 7, announcing the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, along with the first edition of the Commercial Health Insurance Innovative Drug Catalog [1] - The adjustment of the National Drug Catalog is the 8th since the establishment of the National Medical Insurance Administration, adding 114 new drugs, including 50 Class 1 innovative drugs [1] - The first edition of the commercial health insurance innovative drug catalog includes 19 drugs, featuring CAR-T cancer treatment drugs and Alzheimer's disease treatment drugs, indicating a sustained rise in innovative drugs from the perspectives of business development, commercialization, and policy [1] Group 2 - The Guotai Innovative Drug ETF (589720) focuses on innovative drug companies listed on the Sci-Tech Innovation Board, tracking an index of 30 representative high-quality companies, primarily in high-growth biotech [1] - From September 24, 2024, to October 31, 2025, during the market rebound, the Sci-Tech Innovative Drug Index and the Hang Seng Hong Kong Stock Connect Innovative Drug Index increased by 143.70% and 135.34% respectively, suggesting that the Sci-Tech Innovative Drug Index may better capture the elasticity of the Sci-Tech Innovation Board when market risk appetite recovers [1]

Core Insights - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security announced the new National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025) and the Commercial Health Insurance Innovative Drug Catalog (2025), which will be implemented nationwide starting January 1, 2026 [1] Group 1: National Basic Medical Insurance Drug Catalog - The updated National Medical Insurance Drug Catalog adds 114 new drugs, including 50 first-class innovative drugs, while removing 29 drugs that are either not clinically available or can be better replaced by other medications [1] - After the adjustments, the total number of drugs in the catalog increases to 3,253, comprising 1,857 Western medicines and 1,396 traditional Chinese medicines, significantly enhancing coverage for key areas such as oncology, chronic diseases, mental illnesses, rare diseases, and pediatric medications [1] Group 2: Commercial Health Insurance Innovative Drug Catalog - The inaugural Commercial Health Insurance Innovative Drug Catalog includes 19 drugs, which complements the basic medical insurance, laying a foundation for the differentiated development of commercial insurance and basic medical insurance, and establishing a multi-tiered medical security system [1]

Core Insights - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security announced the new National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalogs for 2025, effective from January 1, 2026 [1] Summary by Categories National Medical Insurance Drug Catalog - The updated catalog includes 114 new drugs, of which 50 are first-class innovative drugs [1] - A total of 29 drugs that are either not clinically available or can be better replaced by other medications have been removed [1] - The total number of drugs in the catalog has increased to 3,253, comprising 1,857 Western medicines and 1,396 traditional Chinese medicines [1] - There is a significant enhancement in coverage for key areas such as oncology, chronic diseases, mental health, rare diseases, and pediatric medications [1] Commercial Health Insurance Innovative Drug Catalog - The inaugural commercial health insurance innovative drug catalog includes 19 drugs, which complements the basic medical insurance [1] - This initiative aims to promote the differentiated development of commercial insurance and basic medical insurance, laying the groundwork for a multi-tiered medical security system [1]

Core Viewpoint - The National Healthcare Security Administration announced the 2025 version of the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, along with the first edition of the Commercial Health Insurance Innovative Drug Catalog, which will be implemented starting January 1, 2026 [1] Group 1 - The new drug catalog aims to enhance the accessibility and affordability of essential medications for the public [1] - The implementation of the updated drug lists is expected to influence the pharmaceutical industry significantly, particularly in terms of market dynamics and pricing strategies [1] - The introduction of the Commercial Health Insurance Innovative Drug Catalog indicates a shift towards integrating innovative therapies into health insurance coverage [1]

Core Insights - The 2025 Innovation Drug High-Quality Development Conference was held in Guangzhou on December 7, where the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog was released [1] - This is the 8th adjustment since the establishment of the National Medical Insurance Administration, with the new catalog set to be implemented nationwide on January 1, 2026 [1] - The adjustment adds 114 new drugs, including 50 first-class innovative drugs, while removing 29 drugs that are either not clinically available or can be replaced by better alternatives [1] - The total number of drugs in the catalog increases to 3,253, comprising 1,857 Western medicines and 1,396 traditional Chinese medicines, with significant improvements in coverage for key areas such as cancer, chronic diseases, mental illnesses, rare diseases, and pediatric medications [1] - Additionally, the National Medical Insurance Administration released the first commercial insurance innovative drug catalog, which includes 19 drugs covering rare diseases, neurodegenerative diseases, other solid tumors/blood tumors, and metabolic diseases [1] Summary by Categories Drug Catalog Adjustments - The new drug catalog will include 114 new drugs, with a focus on innovative treatments [1] - 50 of the newly added drugs are classified as first-class innovative drugs [1] - A total of 29 drugs have been removed from the catalog due to lack of clinical supply or better alternatives [1] Coverage and Focus Areas - The total number of drugs in the catalog has increased to 3,253, enhancing the coverage for critical health areas [1] - Key areas with improved coverage include cancer, chronic diseases, mental health, rare diseases, and pediatric medications [1] Commercial Insurance Developments - The first commercial insurance innovative drug catalog includes 19 drugs targeting specific health conditions [1] - The catalog covers treatments for rare diseases, neurodegenerative diseases, solid tumors, blood tumors, and metabolic disorders [1]